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The management of transitional cell carcinoma of the bladder (TCCB) presents a challenge to urological
surgeons due to the diversity of patient factors, stage at presentation and propensity for disease recur-
rence and progression. Advances in the last decade have seen an evolution in techniques for diagnosis,
treatment and ongoing surveillance. A good understanding of our patients, the disease and the available
diagnostic and therapeutic options is essential for the management of this condition. We review the
current literature focusing on the merits of recent advances in this ﬁeld. Given the breadth of the subject,
we have deliberately selected only the most relevant and recent advances already in clinical use.
 2013 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.1. Introduction
Transitional cell carcinoma of the bladder (TCCB) remains the
second commonest urological malignancy after prostate cancer.
Management of the disease and its sequelae represent signiﬁcant
associated morbidity, mortality, and global healthcare costs.1 Inci-
dence rates are highest in the elderly with a 3:1 ratio of male
preponderance.2 TCCB is the most prevalent histological subtype of
bladder cancer (90%), with squamous cell (5%) and adenocarci-
nomas (<2%) much less common.2,3 Of these, approximately 80%
are non-muscle invasive at the time of diagnosis.4 The European
Organisation for Research and Treatment of Cancer (EORTC) pub-
lished disease recurrence rates for non-muscle invasive bladder
cancer (NMIBC) ranging from 15 to 61% at one year, increasing to
31e78% at ﬁve years, compared with progression rate calculations
of <1e17% and 1e45% at one and ﬁve years respectively.5(Table 1)
The diversity of patient factors, stage at presentation, patho-
logical grade and subsequent recurrence is reﬂected in the wide
range of treatment options. This diversity also mandates individ-
ually tailored long-term surveillance programs after initial
management.n NW3 1RX, United Kingdom.
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review, we present the most relevant recent advances in the ﬁeld.
We deliberately focus on those advances in current practice; a
discussion on experimental and evolving technology is beyond the
scope of this review. References were sourced from a MEDLINE
review on the selected topics.
2. Diagnosis and surveillance
2.1. Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) is a cytogenetic test
allowing for the identiﬁcation of aberrations on chromosomes 3, 7, 9
and 17 in shedded urothelial cells in a urine specimen.6e8 FISHmay
be of clinical use in conﬁrming the presence of urothelial cancer in
equivocal or suspicious urine cytology,6 predicting recurrence in
cases of established disease in response to treatment.7,8
In a study of 280 urine specimens of patients with known uro-
thelial carcinoma, FISH was shown to be signiﬁcantly more sensi-
tive than urine cytology across all tumour grades (81% vs 58%,
p ¼ 0.001). There was no difference in the speciﬁcity (98% vs 96%,
p ¼ 0.564).6
A recent single-centre, prospective study of 126 patients iden-
tiﬁed the potential value of FISH analysis in predicting subsequent
disease recurrence in relation to immunomodulatory treatment of
non-invasive bladder cancer with bacillus Calmette-Guérin (BCG)ssociates Ltd.
Table 1
Summary of recent advances in bladder cancer management.
Recent advances Advantages Disadvantages
Fluorescence in situ
hybridization (FISH)
 Non-invasive
 Signiﬁcantly more sensitive than urine cytology
 Poor predictor of subsequent disease progression
 Expensive
Photodynamic diagnosis (PDD)  Sensitive for bladder tumours particularly CIS
Improved tumour recurrence rates compared
to white-light cystoscopy
 Low speciﬁcity
Long-term data to be determined
Narrow Band Imaging (NBI)  Comparable PDD sensitivity
 No intravesical agent required
 Improved tumour recurrence rates compared
to white-light cystoscopy
 Low speciﬁcity
 Long-term data to be determined
EMDA-MMC  Deeper penetration of tissue than PD
 Synergy with BCG
 Increased length of treatment in
combination with BCG
Robotic cystectomy  Improved cosmesis
 Less blood loss
 Reduced intra-operative morbidity
 Reduced hospital stay
 Lacking in long-term data
 Highly specialized
 High costs
 Increased anaesthetic time
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(p ¼ <0.01) in FISH positive samples at two year follow up,
following interval testing.7 There is currently limited evidence to
suggest FISH can predict progression in TCCB.8
2.2. Photodynamic diagnosis
Photodynamic diagnosis (PDD), also known as ‘ﬂuorescence’ or
‘bluelight’ cystoscopy, has been shown to be more sensitive than
white-light cystoscopy at detecting papillary bladder tumours and
carcinoma in situ (CIS) lesions.10 Intravesical instillation of photo-
sensitizing agents: 5-aminalaevulinic acid (5-ALA) or its more
lipophilic hexyl ester; hexaminolevulinate (HAL) (Hexvix) causes
accumulation of photoactive porphyrin in hypermetabolic tissues/
rapidly proliferating cells. This results in selective ﬂuorescence
emission from cancer cells.11 Normal tissue appears blue and sus-
picious tissue appears red under blue light. HAL has a higher for-
mation capacity of photoactive porphyrin at lower pro-drug
concentrations and deeper urothelial penetration compared to 5-
ALA.11 This translates into shorter instillation times and brighter
ﬂuorescence for HAL.12
CIS is often not visible, or distinguishable, from an area of
inﬂammation underwhite-light cystoscopy. Numerous studies have
shown HAL-guided ﬂuorescence cystoscopy is superior at detection
of CIS than white-light cystoscopy,12,13,38 especially when used in
conjunction with urine cytology testing.14 A European multicentre
study by Jocham D et al., demonstrated 96% of all tumours detected
by HAL-PDD compared to 76% using white-light cystoscopy. This
study led to improved treatment for 17% of patients (p< 0.0001).15 A
meta-analysis of 12 prospective trials showed an additional detec-
tion rate of 20% for PDD (range: 5e49%). In CIS patients, the addi-
tional detection rate with PDD was 39% (range: 17e78%).16
PDD is associated with higher false positive results compared to
white-light cystoscopy. One study reported a PDD false positive
detection rate of 8.8%e62.5% vs 7.1%e47% for white-light cystos-
copy.16 False positive ﬂuorescence may be induced by inﬂamma-
tion, recent transurethral resection of bladder tumour (TURBT),
recent BCG instillation or oblique illumination at the bladder
neck.17,18 Mostaﬁd H et al. conducted amulticentre prospective trial
and reported only a 1% difference in HAL-PDD and white-light
cystoscopy.19 The reduction in false positivity rates may be due to
increasing PDD experience and equipment improvements.13
Themeta-analysis reported PDD-TURBT recurrence-free survival
was 15.8%e27% higher at 12 months and 12%e15% higher at 24
months than the white-light TURBT group.16 Similar 12-month
recurrence rates have also been reported.8 Geavlete et al. showed
signiﬁcantly improved recurrence rates at 3,12 and24months in the
HAL-PDD group compared to the white-light cystoscopy group.11The beneﬁt of PDD is highest in CIS patients and has been clearly
demonstrated in a number of studies. Despite a limited increase in
false positive detection rates, PDD use is still recommended in view
of its improved detection compared with white-light cystoscopy.38
The value of ﬂuorescence cystoscopy in relation to bladder cancer
progression rate or long-term survival has yet to be determined.
European Association of Urology (EAU) 2011 guidelines state that
PDD should be advocated in all patients suspected of having high-
grade individual tumours or recurrences, (i.e. positive urine
cytology, negative white-light cystoscopy) and especially known
CIS and multifocal disease.172.3. Narrow band imaging
Narrow band imaging (NBI) represents a novel imaging mo-
dality, independent of ﬂuorescent agents, aimed at improving the
detection of non-muscle invasive bladder cancers (NMIBC). It ﬁlters
white light into two narrow bandwidths of about 415 nm (blue
light) and 540 nm (green light). These are strongly absorbed by
haemoglobin, penetrating only the superﬁcial layers of the tissue.21
This facilitates enhancement of the contrast between normal uro-
thelium and well vascularised bladder tumours.9
NBI has improved detection rates compared with white-light
cystoscopy for NMIBC. There is evidence supporting improved
TCCB detection rates in ﬂexible and rigid NBI-cystoscopy when
compared with white-light cystoscopy.13,22 A NBI-TURBT group had
a residual tumour rate of 15% compared to a matched white-light
TURBT cohort of 30.5%.23 Herr H et al. found that follow up with
NBI-cystoscopy was associated with lower incidence of tumour
recurrence and longer recurrence-free survival time compared
with white-light cystoscopy.24 A more recent study in which 148
subjects were included in a prospective randomised trial reported a
one-year recurrence risk of 32.9% in the NBI-TURBT group
compared to 51.4% in the white-light TURBT group.25 The study’s
authors concluded that NBI-TURBT reduces the recurrence risk at
one-year of NMIBC by at least 10%.
Similar to PDD, NBI has a low speciﬁcity. One study reported a
diagnostic speciﬁcity of 27.8%. The false positive rates can occur
with inﬂammation, cystitis and trauma, which may resemble
vascular changes in TCCB.263. Treatment
3.1. Electromotive drug administration (EMDA)
Electromotive drug administration (EMDA) is an emerging
technique to enhance the delivery of intra-vesical mitomycin
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resis, whereby an electrical current can accelerate the diffusion of a
charged particle (MMC) through a membrane (bladder wall). This
can be achieved in practice with activation of electrodes in the
catheter and on the patient’s skin during instillation ofMMC. In vitro
and in vivo studies have demonstrated an increase concentration of
MMC within the lamina propria and muscularis layers when
compared with passive diffusion (PD) modes of administration.4e27
A prospective randomized trial has shown EMDA-MMC to be
superior to PD-MMC regarding complete response at 6 months
(58.3% vs 30.5%, p ¼ 0.012) and equivalence with BCG for CIS pa-
tients with or without T1 tumours.4 The longer-term effects on
recurrence and progression rates are yet to be determined.
3.2. EMDA and BCG combination therapy
This regimen involves combination therapy with intravesical
BCG and EMDA-MMC for CIS and T1 tumours. Nine weekly in-
stallations are given, with 6 instillations of BCG interspaced with 3
instillations of EMDA-MMC.28 Maintenance therapy is initiated if
patient is disease-free at three months post-resection with once
monthly MMC, MMC then BCG (i.e. three month cycles) for nine
months after cystoscopy.28
In a landmark phase 3 randomised trial involving 212 patients
with superﬁcial high risk bladder cancer, combined BCG and
EMDA-MMC was superior to BCG alone in disease-free interval (69
vs 21 months, p ¼ 0.012), recurrence rates (41.9% vs 57.9%,
p ¼ 0.0012), progression rates (9.3% vs 21.9%, p ¼ 0.004) and
crucially disease-speciﬁc mortality (5.6% vs 16.2% p ¼ 0.01).28 Such
remarkable results are yet to be validated by another centre.
3.3. Pre-operative EMDA-MMC
Pre-operative EMDA-MMC is postulated to be effective in
destroying tumour cells within the wall of the bladder before
resection. This may be of beneﬁt over PD-MMC given post-
operatively which is effective at destroying free tumour cells in
the bladder, but less so any residual tumour cells in the bladder
wall.29 A randomized trial showed patients having pre-operative
EMDA-MMC to have a longer disease-free interval than post-
operative PD-MMC and TURBT alone (52, 16 and 12 months,
p < 0.001) and a lower recurrence rate (38%, 59% and 64%,
p < 0.001). There were no signiﬁcant differences in progression
rates.29
3.4. Robot-assisted radical cystectomy
While open radical cystectomy (ORC) remains the gold standard
treatment for muscle invasive bladder cancer (MIBC),3 advances
and increasing experience in robotic surgery have led to robot-
assisted radical cystectomy (RARC) becoming a mainstream alter-
native to open surgery.24e36 Until recently, urinary diversions have
been performed extra-corporeally only. With increasing experi-
ence, a few centres are switching to intra-corporeal diversions.
In a standard RARC, the cystectomy and extended pelvic node
dissection are completed robotically, with the ileal conduit or
neobladder formed extra-corporeally through a small midline or
transverse incision after undocking of the robot.
In a randomized trial of 41 patients, RARC was shown to have
less blood loss (median 200 ml vs 600 ml, p < 0.0001), quicker
return of bowel function (median 3 days vs 4 days, p ¼ 0.0008) and
lower analgesic requirements (median morphine equivalents
87.5 mg vs 121.5 mg, p¼ 0.0044). There was a shorter length of stay
in the RARC group (median 4 days vs 6 days, p ¼ 0.2387), but this
did not reach statistical signiﬁcance. There were no differences inClavien graded complications.30 Direct comparison of complication
rates across larger RARC and ORC series is difﬁcult due to selection
bias in RARC patients.36
Despite initial criticism, RARC has been shown to have equiva-
lent short-term oncological outcomes in terms of positive margin
rates and lymph node yield.30,32e35 Long-term oncological and
functional outcomes in a limited cohort of patients reported by
Khan et al. appear equivalent to that of ORC.39
3.5. Robotic-assisted intra-corporeal diversion
Further advances in robotic surgery have allowed for total intra-
corporeal reconstruction of an ileal conduit or neobladder after
RARC, with the potential for improved cosmesis, less analgesia and
quicker return of bowel function.36
In the largest collaboration to date, the International Robotic
Cystectomy Consortium (IRCC) reported a non-randomised series
of RARC from 18 centres. A total of 167 patients who had
intra-corporeal diversion (106 conduits, 61 neobladders) were
compared with 768 patients who underwent extra-corporeal
diversion (570 conduits, 198 neobladders). The operating time
was equivalent in the two groups (414 min). The intra-corporeal
group had a longer length of stay (median 9 days vs 8 days,
p ¼ 0.036) but experienced a lower 90-day complication rate (40%
vs 50%, p ¼ 0.019). Overall, the intra-corporeal group was 32% less
likely to have a major complication. There was no difference in the
re-operation rate between the two groups.37 To date, there are no
randomized studies comparing intra and extra-corporeal recon-
struction after RARC. As yet, there are no long-term follow up data
on functional outcomes from intra-corporeal urinary diversion.
4. Conclusion
The last decade has seen several advances in the diagnosis and
treatment of TCCB, which are now in clinical use. The technique of
FISH helps solve the age-old problem of suspicious urine cytology
in patients with suspected urothelial cancer and may have a role in
predicting response to treatment. PDD and NBI techniques have
increased detection of bladder cancer at cystoscopy and allowed for
higher quality resection. EMDA has improved delivery of intra-
vesical MMC and shows great promise in combination with BCG
for superﬁcial high-grade disease. Robotic techniques have revo-
lutionized cystectomy allowing a less morbid procedure with
equivalent oncological outcomes. These advances have the poten-
tial to improve the accuracy of our diagnosis, reduce recurrence and
possibly progression, as well as reduce surgical morbidity. The
downside is that new advances carry increased cost, limiting the
technology to selected tertiary referral centres. We keenly await
what the next decade will bring to the ﬁeld.
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